Abstracts tagged "Uric Acid, Urate"

Abstract Number: 0550 • ACR Convergence 2022
Improving the Accuracy of Automated Gout Flare Ascertainment Using Natural Language Processing of Medical Records and Linked Medicare Claims Data for Real-world Comparative Effectiveness Research
Kazuki Yoshida, Tianrun Cai, Lily G Bessette, Erin Kim, Su Been Lee, Luke E Zabotka, Alec Sun, Julianna M. Mastrorilli, Theresa A. Oduol, Jun Liu, Daniel Solomon, Katherine Liao and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Gout flares are challenging to study using large real-world data because flares are episodic with varying severity and clinical manifestations. Furthermore, there is no…
Abstract Number: 1814 • ACR Convergence 2022
Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
Abdul Abdellatif¹, Yan Xin², Jason Chamberlain³, Lin Zhao², Katya Cherny³, Brad Marder⁴, John D Scandling⁵ and kenneth saag⁶, ¹Kidney Hypertension Transplant Clinic Clear Lake Specialties, Webster, TX, ²Horizon Therapeutics, Deerfield, IL, ³Horizon Therapeutics plc, Deerfield, IL, ⁴Horizon Therapeutics, Denver, CO, ⁵Stanford University School of Medicine, Division of Nephrology, Palo Alto, CA, ⁶University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Immunomodulator co-therapy with pegloticase has been shown to reduce immunogenicity (anti-drug antibody [ADA] development), which markedly improves response rates with pegloticase while reducing risk…
Abstract Number: 1006 • ACR Convergence 2022
Impact of Uric Acid Levels on Clinical and Radiographic Characteristics in Psoriatic Arthritis and Response to Secukinumab: A Pooled “Post Hoc” Analysis from Five Phase 3 Studies
Renaud FELTEN¹, Laura Widawski², Lionel Spielmann², Corine Gaillez³, Weibin Bao⁴, Hugh O’Neill⁵, jacques-eric gottenberg⁶, Pierre-Marie Duret² and Laurent Messer⁷, ¹Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ²Colmar Civilian Hospitals, Colmar, France, ³Novartis Pharma AG, Basel, Switzerland, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Ireland Limited, Dublin, Ireland, ⁶Strasbourg University Hospital, Strasbourg, France, ⁷Colmar Civil Hospitals, Colmar, France
Background/Purpose: Hyperuricemia (HU), a common metabolic abnormality, may result in development of gout, which is an inflammatory arthritic condition1,2. Patients (pts) with psoriasis (PsO)/psoriatic arthritis…
Abstract Number: 1826 • ACR Convergence 2022
Association of High Uric Acid Levels with Low Bone Mineral Density in Pre- but Not Post-menopausal Women with Rheumatoid Arthritis
Sandra Hermann¹, Andriko Palmowski¹, Bukrhard Muche², Kay-Geert Hermann³, Edgar Wiebe¹ and Frank Buttgereit⁴, ¹Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ²Charité University Hospital, CCM, Berlin, Germany, ³Charité - Universitätsmedizin Berlin, Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Uric acid is controversially discussed regarding its effect on bone health. Higher uric acid levels have been associated with higher T-scores and fewer bone…
Abstract Number: 1132 • ACR Convergence 2022
Interaction of LOC100507053, ADH1B, and ADH1C with Alcohol Consumption for Elevated Serum Urate Levels and Gout in People of European Ethnicity
Min Hui Chuah¹, Ruth Topless², Gregory Gamble¹, Nicholas Sumpter³, Lisa Stamp⁴, Tony Merriman² and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Otago, Christchurch, New Zealand
Background/Purpose: Alcohol consumption is a risk factor for hyperuricaemia and gout. Multiple single nucleotide polymorphisms (SNPs) have been identified as associated with both habitual alcohol…
Abstract Number: 1829 • ACR Convergence 2022
Efficacy and Safety of Allopurinol and Febuxostat in Patients with Gout and Chronic Kidney Disease: A Subgroup Analysis of the STOP Gout Study
Lindsay Helget¹, Anne Davis-Karim², James O'Dell¹, Ted Mikuls³, Jeff Newcomb¹, Maria Androsenko⁴, Mary Brophy⁴, Bryant England¹, Ryan Ferguson⁴, Michael Pillinger⁵, Tuhina Neogi⁶, Hongsheng Wu⁴ and Paul Palevsky⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ³Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, ⁴VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ⁵NYU Grossman School of Medicine, New York, NY, ⁶Boston University School of Medicine, Boston, MA, ⁷University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh
Background/Purpose: Urate lowering therapy (ULT) is a cornerstone in the treatment of gout, which afflicts over 2 million individuals with chronic kidney disease (CKD) in…
Abstract Number: 1206 • ACR Convergence 2022
Association Between Different Alcoholic Beverages and Serum Urate Level: A Cross-Sectional Study Using Large Medical Checkup Data
Sho Fukui¹, Masato Okada², Mahbubur Rahman³, Takehiro Nakai², Hiromichi Tamaki², Hiroki Matsui⁴, Atsushi Shiraishi⁵, Mitsumasa Kishimoto⁶, Hiroshi Hasegawa⁷, Takeaki Matsuda⁷ and Kazuki Yoshida⁸, ¹Kyorin University Hospital, Tokyo, Japan, ²St. Luke's International Hospital, Tokyo, Japan, ³Graduate School of Public Health, St. Luke’s International University, Tokyo, Japan, ⁴Clinical Research Support Office, Kameda Medical Center, Kamogawa, Japan, ⁵Emergency and Trauma Center, Kameda Medical Center, Kamogawa, Japan, ⁶Kyorin University School of Medicine, Yokohama, Japan, ⁷Kyorin University, Tokyo, Japan, ⁸Brigham and Women's Hospital, Boston, MA
Background/Purpose: Alcohol consumption is associated with increased serum urate levels. However, data regarding the differences in the extent of the association between various types of…
Abstract Number: 1410 • ACR Convergence 2022
Subclinical Atherosclerosis Is Not Related with Acid Uric in Rheumatoid Arthritis: Study of 1005 Patients of a Single University Hospital
Fabricio Benavides Villanueva¹, Cristina Corrales¹, Ivan Ferraz Amaro², Nuria Vegas Revenga³, Ricardo Blanco⁴, Miguel Angel Gonzalez Gay⁵ and Alfonso Corrales⁶, ¹Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, ³Hospital Galdakao- Usansolo, Galdakao, Spain, ⁴Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁵Hospital Universitario Marques de Valdecilla, Lugo, Spain, ⁶Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
Background/Purpose: Rheumatoid Arthritis (RA) and Gout are related with increased cardiovascular (CV) disease. Carotid plaques and increased carotid intima-media thickness (cIMT) are surrogate markers of…
Abstract Number: 1579 • ACR Convergence 2022
The TICOG Study: Tight Control of Gout – A Randomized, Controlled Trial of Targeted versus Conventional Treatment for Gout Including Ultrasonography
Sarah Black, Natalie McKee, Jonathan McKnight, Annmarie McShane, Adrian Pendleton, Taggart Alister and Gary Wright, Musgrave Park Hospital, Belfast Health and Social Care Trust, Belfast, Northern Ireland, United Kingdom
Background/Purpose: Gout is a common inflammatory arthritis triggered by deposition of monosodium urate crystals in joints, bone and soft tissues, with a prevalence of 1-4%…
Abstract Number: 1583 • ACR Convergence 2022
Race and Disease Severity Predict Reduced Response to Treat-to-Target Urate Lowering Therapy in Gout: Post-hoc Analysis of a Multicenter, Randomized, Double-Blind, Non-Inferiority Trial
Lindsay Helget¹, James O'Dell¹, Jeff Newcomb¹, Maria Androsenko², Mary Brophy², Anne Davis-Karim³, Bryant England¹, Ryan Ferguson², Michael Pillinger⁴, Tuhina Neogi⁵, Paul Palevsky⁶, Hongsheng Wu² and Ted Mikuls⁷, ¹University of Nebraska Medical Center, Omaha, NE, ²VA Boston Cooperative Studies Program Coordinating Center, Boston, MA, ³VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁴NYU Grossman School of Medicine, New York, NY, ⁵Boston University School of Medicine, Boston, MA, ⁶University of Pittsburgh School of Medicine, Pittsburgh, Pittsburgh, ⁷Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The ACR recommends a treat-to-target strategy in the management of gout, involving titration of urate lowering therapy (ULT) to a serum urate (SU) goal…
Abstract Number: L05 • ACR Convergence 2021
Phase 2 Study Results from a Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate Efficacy and Safety of Tigulixostat, a Novel Non-purine Selective Xanthine Oxidase Inhibitor, in Gout Patients with Hyperuricemia
Robert Terkeltaub¹, JuneSik Mune², Jieun Lee³ and Kenneth Saag⁴, ¹VA/UCSD, San Diego, CA, ²LG Chem, Ltd., Seoul, ³LG Chem, Ltd., Seoul, South Korea, ⁴The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Gout can be effectively managed by inhibiting synthesis of uric acid. Tigulixostat is a novel non-purine selective xanthine oxidase inhibitor which lowers production of…
Abstract Number: L06 • ACR Convergence 2021
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment Strategies on Cardiovascular Outcomes Using Observational Data: Causal Inference Approach
Kazuki Yoshida, Jun Liu, Daniel Solomon, Robert J Glynn and Seoyoung Kim, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy (ULT) has been questioned.…
Abstract Number: 1569 • ACR Convergence 2021
Effect of Elevated Serum Urate on Kidney Function: Analysis of a Randomized Controlled Trial of Inosine Supplementation
Nicola Dalbeth¹, Borislav Mihov¹, Angela Stewart¹, Gregory Gamble¹, Tony Merriman², David Mount³, Lisa Stamp⁴, Ian Reid¹ and Anne Horne¹, ¹University of Auckland, Auckland, New Zealand, ²University of Alabama at Birmingham, Dunedin, New Zealand, ³Brigham and Women's Hospital, Boston, MA, ⁴University of Otago, Christchurch, Christchurch, New Zealand
Background/Purpose: Observational studies have reported that serum urate associates with development and progression of kidney disease. However, it is uncertain whether elevated serum urate directly…
Abstract Number: 1570 • ACR Convergence 2021
AR882, a Novel Uricosuric Agent, Exhibited Favorable Pharmacokinetic Profile and Balanced Excretion and Metabolic Pathways in a Human AME Study
Rongzi Yan¹, zancong shen², Elizabeth Polvent³, vijay hingorani⁴, Shunqi Yan⁵ and Litain Yeh⁶, ¹Arthrosi Therapeutics, Inc, Irvine, CA, ²Arthrosi Therapeutics, Inc., San Diego, CA, ³Arthrosi Therapeutics, Inc., Roseville, CA, ⁴Vanguard Healthsciences, Inc., San Diego, CA, ⁵Arthrosi Therapeutics, Inc., Laguna Hills, CA, ⁶Arthrosi Therapeutics, Inc., Irvine, CA
Background/Purpose: AR882, a novel uric acid transporter 1 (URAT1) inhibitor is being developed for the treatment of gout with hyperuricemia. In Phase 1 and Phase…
Abstract Number: 1572 • ACR Convergence 2021
Ultrasound Signs of Gout in a Population with Asymptomatic Hyperuricemia
Bilal Bengana¹, Aicha Ladjouze², Nabil Baramtane Raaf³, Chaffa Aimeur⁴, Soraya Ayoub⁵, Abdenour Boukabous⁶ and Salima Lefkir-Tafiani⁷, ¹University Hospital of Beni Messous Algiers - Rheumatology Department, Algiers, Algeria, ²Specialized hospital establishment of Benaknoune, Rheumatology, Algiers, Algeria, ³Hospital of Bitraria, Biochemistry, El Biar, Algiers, Algeria, ⁴University hospital of Mustapha Bacha, Radiology, Sidi Mhamed, Algiers, Algeria, ⁵University hospital of Beni Messous, Internal Medicine, BeniMessous, Algiers, Algeria, ⁶University Hospital of Beni Messous Algiers- Rheumatology Department, Algiers, Algeria, ⁷University Hospital of Beni Messous Algiers - Rheumatology Department, Benimessous, Algeria
Background/Purpose: Hyperuricemia is a common biological abnormality, often clinically asymptomatic. However, it can announce a gout and be linked to many diseases such as metabolic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].